ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Efficacy"

  • 2020 American Transplant Congress

    Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients

    J. Ahn1, S. Bae1, K. Lentine2, M. Schnitzler2, G. Hess3, D. Segev1, M. McAdams-DeMarco1

    1Johns Hopkins University, Baltimore, MD, 2Saint Louis University, St. Louis, MO, 3Drexel University, Philadelphia, PA

    *Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2…
  • 2020 American Transplant Congress

    Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation

    K. Bzeizi, A. Albenmousa, M. Shawkat, W. Alhamoudi, S. Alabad, R. Troisi, D. Broering

    KFSHRC, Riyadh, Saudi Arabia

    *Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…
  • 2020 American Transplant Congress

    Comparison of Oropharyngeal Candidiasis Outcomes in Renal Transplant Recipients Receiving Nystatin or No Antifungal Prophylaxis

    T. Q. Ky, L. Cotiguala, L. Fitzgerald, K. McMurry, J. Park, S. Tischer

    Pharmacy, University of Michigan, Michigan Medicine, Ann Arbor, MI

    *Purpose: Oropharyngeal candidiasis (OC) rate in the absence of antifungal prophylaxis has been reported as low as 7.4% after renal transplant. Due to perceived low…
  • 2020 American Transplant Congress

    Brincidofovir for Adenovirus Disease in Adult Renal Transplant Recipients: A Case Series

    F. Zervou1, I. Zacharioudakis1, S. A. Mehta2, H. J. Neumann2

    1Infectious Diseases, New York University Langone, New York, NY, 2New York University Langone Transplant Institute, New York, NY

    *Purpose: Adenovirus infection can lead to disease in solid organ transplant recipients, including disease of the allograft. Treatment options for severe disease are limited. Brincidofovir…
  • 2020 American Transplant Congress

    Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides Difficile Infection among Transplant Recipients

    V. Bajrovic1, T. Johnson2, A. Howard2, L. Allen3, G. Barber2, K. Schwarz2, M. Huang3, M. Abidi1, E. Benamu3, P. Ramanan3, M. Miller4

    1Division of Infectious Diseases, University of Colorado, Denver, CO, 2Department of Pharmacy, University of Colorado, Aurora, CO, 3Division of Infectious Diseases, University of Colorado, Aurora, CO, 4Department of Pharmacy, University of Colorado, Denver, CO

    *Purpose: Clostridioides difficile is an urgent health threat associated with significant morbidity and mortality. Recipients of solid organ (SOT) and hematopoietic-cell transplantations (HCT) are at…
  • 2020 American Transplant Congress

    Organ and Tissue Donation Education for Transplant Patients Staying at a Transplant Hospitality House Leads to Successful Cornea Donation

    T. Giordano1, L. Suplee2, J. L. Weinstock3, R. D. Hasz4, H. M. Nathan5

    1Family Support Manager, Caregiver Lifeline Program, Gift of Life Family House, Philadelphia, PA, 2Director, Transplant Information Center, Gift of Life Donor Program, Philadelphia, PA, 3Vice President and General Counsel, Gift of Life Donor Program, Philadelphia, PA, 4Vice President of Clinical Services, Gift of Life Donor Program, Philadelphia, PA, 5President and CEO, Gift of Life Donor Program, Philadelphia, PA

    *Purpose: A transplant hospitality house (THH) serving multiple transplant centers is directly connected to its region’s Organ Procurement Organization (OPO) and offers formal education to…
  • 2020 American Transplant Congress

    Effect of DSA-Free Heart Allocation

    V. Patel1, M. Skeans2, T. Cascino1, R. Davies3, M. Colvin1

    1University of Michigan, Ann Arbor, MI, 2SRTR, Minneapolis, MN, 3UT Southwestern, Dallas, TX

    *Purpose: Currently, donation service area (DSA) is the first geographic unit for heart allocation, which creates discrepancies in access for high-urgency candidates. We studied the…
  • 2020 American Transplant Congress

    Effect of Rituximab Dose as Induction Therapy in ABO Incompatible Living Kidney Transplantation A Systemic Review and Network Meta Analysis

    S. Hwang1, W. Park2, K. Kim1, S. Lee1, J. Song1

    1Inha University, Incheon, Korea, Republic of, 2Keimyung University, Daegu, Korea, Republic of

    *Purpose: ABO-incompatible living kidney transplantation (ABOILKT) has steadily become more widespread. However, the optimal immunosuppressive regimen for ABOILKT remains uncertain. We aimed to determine the…
  • 2020 American Transplant Congress

    Impact of Nursing Education on Organ Donation

    J. Yeh1, M. Corcoran2, M. Jarrett2, V. Nair1, L. Teperman1

    1Northwell Health, Manhasset, NY, 2Northwell Health, New Hyde Park, NY

    *Purpose: Organ transplantation is the gold-standard for patients with end-stage organ disease. For organ donation to occur, potential donors need to be identified and referred…
  • 2020 American Transplant Congress

    Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform

    S. Berger1, M. Bakr1, F. Bemelman1, R. Danguilan1, H. De Fijter1, D. Han1, M. Kim1, E. Mor1, A. Patel1, M. Hernandez Gutierrez2, A. Gawai2, Y. Watarai1

    1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

    *Purpose: To assess the efficacy and safety outcomes in de novo renal transplant (RTx) recipients receiving everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolate with…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences